Table 1 Demographic and clinical data in cohort patients
Variables | Entire patient (n = 244) |
|---|---|
Age (years) | 11.2 (0.3–17.9) |
Sex (Male/Female) | 168/76 |
Body weight, z-score | − 0.8 ± 1.8 |
Height, z-score | − 0.9 ± 1.6 |
Body mass index, z-score | −0.3 ± 1.4 |
Chronic kidney disease stage | |
 I | 45 (18.4) |
 II | 47 (19.3) |
 III | 85 (34.8) |
 IV | 45 (18.4) |
 V | 22 (9.0) |
Hypertension (n = 220) | 157 (71.4) |
 Systolic blood pressure > 95 percentile (n = 204) | 27 (13.2) |
 Diastolic blood pressure > 95 percentile (n = 204) | 47 (23.0) |
 Overall blood pressure > 95 percentile (n = 204) | 58 (28.4) |
 Patients receiving antihypertensive medications (n = 242) | 141 (58.3) |
 Angiotensin-converting-enzyme inhibitors or angiotensin II receptor blockers | 137 (97.2) |
 Other medications | 4 (2.8) |
Laboratory data | |
 Hemoglobin (g/dL) | 12.4 ± 1.8 |
 Estimated glomerular filtration rate (ml/min/1.73 m2) | 57.4 ± 38.2 |
 Serum Ca (mg/dL) | 9.5 ± 0.7 |
 Serum P (mg/dL) | 4.8 ± 0.8 |
 Intact parathyroid hormone (pg/mL) | 55.2 (5.8–1244.0) |
Echocardiography | |
 Left ventricular mass index (g/m2.7) | 37.0 ± 13.0 |
 Patients with left ventricular hypertrophy | 97/242 (40.1) |
 Early diastolic velocity ratio (E/E’) | 7.4 ± 3.0 |